Online Program Home
My Program

Abstract Details

Activity Number: 48
Type: Invited
Date/Time: Sunday, July 31, 2016 : 4:00 PM to 5:50 PM
Sponsor: Biometrics Section
Abstract #318109
Title: Alzheimer's Disease Severity, Objectively Determined and Measured
Author(s): Alden Gross* and Jeannie M. Leoutsakos and Marilyn Albert and Dan M. Mungas and Richard Norman Jones
Companies: Johns Hopkins Bloomberg School of Public Health and The Johns Hopkins University and The Johns Hopkins University and University of California at Davis and Brown University
Keywords: alzheimer's disease ; latent variable modeling ; SEM ; ADNI ; BIOCARD ; biomarkers

AD biomarkers from brain imaging, neuropathology, and cognitive testing provide distinct information about pathophysiology of AD over segments of the clinical spectrum from preclinical to clinical AD. We derived a measure of AD severity based on several biomarkers using latent variable modeling. We used data from ADNI (N=2861) and validated findings in BIOCARD (N=347). We evaluated criterion validity for distinguishing diagnostic groups and construct validity by evaulating rates of change in AD severity. The AD severity factor distinguishes AD from cognitively normal (AUC=0.94) and cognitively normal from MCI (AUC=0.87). Among ADNI MCI, worsening scores predict faster conversion to AD (HR=1.17, 95%CI: 1.13,1.22). The pace of change in AD severity is steepest among converters, with persisting differences by baseline diagnostic status. Results suggest our content-valid latent variable measurement model is a reasonable approach for grading AD severity across a broad spectrum.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association